Daraxonrasib (RMC-6236) Mechanism of Action: RAS Inhibition in Pancreatic Cancer Cell Research

Daraxonrasib (RMC-6236) MOA：Targeting RAS/RAS Signaling Pathway for Pancreatic Ductal Adenocarcinoma (PDAC)

🎯 check Daraxonrasib (RMC-6236) product page

Daraxonrasib is a potent pan-KRAS inhibitor. It affects RAS signaling by targeting RAS(ON), inhibiting cell viability.

Primary Applications and Mechanism of Action

Jump to: